CYTKNasdaqPharmaceutical PreparationsFiscal year ends December 31
CYTOKINETICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$62.65+0.70 (+1.13%)
Close on Oct 19, 2026
- Market cap
- $8.28M
- P/E (TTM)
- –
- Dividend yield
- –
Cytokinetics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Cytokinetics | Industry median |
|---|---|---|
| Market Cap | $8.71B | $166.30M |
| Enterprise Value | $7.29B | $87.12M |
| PS Ratio | 128.71 | 3.60 |
Enterprise value
| Measure | Cytokinetics | Industry median |
|---|---|---|
| EV / Sales | 107.66 | 2.43 |
Income (trailing twelve months)
| Measure | Cytokinetics | Industry median |
|---|---|---|
| Revenue | $67.67M | $57.94M |
| Operating Income | -$707.91M | -$21.49M |
| Net Income | -$894.00M | -$22.46M |
| EBITDA | -$695.36M | -$17.14M |
Margins
| Measure | Cytokinetics | Industry median |
|---|---|---|
| Operating Margin | -1046.1% | -44.5% |
| Profit Margin | -1321.1% | -39.2% |
| EBITDA Margin | -1027.6% | -31.3% |
| FCF Margin | -858.2% | -8.85% |
Returns
| Measure | Cytokinetics | Industry median |
|---|---|---|
| Return on Assets (ROA) | -56.8% | -41.0% |
| Return on Capital Employed (ROCE) | -40.6% | -38.0% |
Growth
| Measure | Cytokinetics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -21.1% | 6.01% |
| Revenue Growth (3Y CAGR) | -2.36% | 2.25% |
| Revenue Growth (5Y CAGR) | 9.54% | 6.42% |
Balance sheet
| Measure | Cytokinetics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $1.70B | $62.64M |
| Total Debt | $275.56M | $120.13M |
| Net Cash (Debt) | $1.42B | $15.77M |
| Net Cash Per Share | $10.25 | $0.66 |
| Equity (Book Value) | -$173.49M | $48.61M |
| Book Value Per Share | -$1.25 | $1.36 |
| Tangible Book Value | -$173.49M | $23.01M |
| Working Capital | $1.03B | $75.09M |
Financial position
| Measure | Cytokinetics | Industry median |
|---|---|---|
| Current Ratio | 6.66 | 3.30 |
| Quick Ratio | 9.50 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Cytokinetics | Industry median |
|---|---|---|
| Operating Cash Flow | -$555.45M | -$12.39M |
| Capital Expenditures | -$25.26M | -$1.07M |
| Free Cash Flow | -$580.72M | -$20.34M |
| FCF Per Share | -$4.18 | -$0.42 |
Efficiency
| Measure | Cytokinetics | Industry median |
|---|---|---|
| Asset Turnover | 0.04 | 0.38 |
| Revenue Per Employee | $100.55K | $398.96K |
| Profits Per Employee | -$1.33M | -$705.27K |
| Employee Count | 673 | 74 |
Dividends and yields
| Measure | Cytokinetics | Industry median |
|---|---|---|
| Earnings Yield | -10.3% | -22.8% |
| FCF Yield | -6.67% | -9.02% |
Shares
| Measure | Cytokinetics | Industry median |
|---|---|---|
| Shares Outstanding | 139,023,000 | 58,139,000 |
| Shares Change (YoY) | 5.08% | 11.1% |
| Float | 138,078,000 | 49,154,900 |
| Shares Held by Insiders | 0.68% | 11.6% |
| Shares Held by Institutions | 115.4% | 59.4% |
Scores
| Measure | Cytokinetics | Industry median |
|---|---|---|
| Altman Z-Score | -0.88 | -0.27 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Cytokinetics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.